Verition Fund Management’s Tenax Therapeutics TENX Stock Holding History

Verition Fund Management’s Portfolio TENX Stock Details TENX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$217K	Buy	+13,589	New	+$184K	﹤0.01%	1927
2023 Q2	–	Sell	-545	Closed	-$20.3K	–	2541
2023 Q1	$20.3K	Buy	+545	New	+$56.8K	﹤0.01%	2008
2018 Q1	–	Sell	-1	Closed	-$16K	–	1312
2017 Q4	$16K	Hold	1	–	–	﹤0.01%	844
2017 Q3	$12K	Hold	1	–	–	﹤0.01%	1128
2017 Q2	$24K	Hold	1	–	–	﹤0.01%	884
2017 Q1	$18K	Hold	1	–	–	﹤0.01%	1132
2016 Q4	$63K	Hold	1	–	–	0.01%	1121
2016 Q3	$74K	Hold	1	–	–	0.01%	1090
2016 Q2	$82K	Hold	1	–	–	0.01%	843
2016 Q1	$66K	Hold	1	–	–	0.01%	677
2015 Q4	$105K	Hold	1	–	–	0.02%	405
2015 Q3	$78K	Hold	1	–	–	0.02%	484
2015 Q2	$145K	Hold	1	–	–	0.03%	522
2015 Q1	$151K	Hold	1	–	–	0.02%	333
2014 Q4	$177K	Sell	1 -1	-50%	-$121K	0.04%	255
2014 Q3	$197K	Hold	2	–	–	0.03%	572
2014 Q2	$306K	Hold	2	–	–	0.03%	405
2014 Q1	$278K	Buy	+2	New	+$396K	0.04%	295

Other funds holding TENX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Verition Fund Management's TENX Position: Q1 2026 in Review

Verition Fund Management opened a new position in Tenax Therapeutics (TENX) in Q1 2026: 13,589 shares worth $217K. The stake represents ﹤0.01% of the portfolio and ranks #1927 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in TENX as recently as Q1 2023.

Verition Fund Management first reported a position in TENX in Q1 2014 and has held it in 18 quarters since. The position peaked at $306K in Q2 2014. 80 funds tracked by Wall St. Rank hold TENX as of Q1 2026.

Verition Fund Management held 13,589 shares of Tenax Therapeutics worth $217K as of Q1 2026.
Tenax Therapeutics was a new Verition Fund Management position in Q1 2026.
Tenax Therapeutics made up ﹤0.01% of Verition Fund Management's portfolio in Q1 2026, its #1927 holding.
Verition Fund Management first reported a position in Tenax Therapeutics in Q1 2014 and has held it in 18 quarters since.
Verition Fund Management's Tenax Therapeutics position peaked at $306K in Q2 2014.
80 funds tracked by Wall St. Rank held Tenax Therapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.